deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03236935

Phase Ib of L-NMMA and Pembrolizumab

Phase Ib Trial of L-NMMA in Combination with Pembrolizumab in Patients with Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients with Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors

Sponsor: The Methodist Hospital Research Institute

Conditions Classical Hodgkin Lymphoma DNA Repair-Deficiency Disorders Head and Neck Squamous Cell Carcinoma Malignant Melanoma Non-Small Cell Lung Cancer Urothelial Carcinoma Bladder
Interventions L-NMMA Pembrolizumab
Updated 14 times since 2017 Last updated: Mar 7, 2025 Started: Aug 3, 2018 Primary completion: Oct 31, 2021 Completion: Dec 28, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Classical Hodgkin Lymphoma and DNA Repair-Deficiency Disorders, this trial is ongoing. The trial is conducted by The Methodist Hospital Research Institute and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Sep 2019 · 9 months · monthly snapshot~Sep 2019 – ~Nov 2020 · 14 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 17 months · monthly snapshot

Change History

14 versions recorded

  1. Apr 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1

▶ Show 9 earlier versions

  1. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Oct 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  3. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  4. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  5. Sep 2019 — Nov 2020 [monthly]

    Recruiting PHASE1

  6. Dec 2018 — Sep 2019 [monthly]

    Recruiting PHASE1

  7. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  8. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Sep 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The Methodist Hospital Research Institute
Data source: The Methodist Hospital Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations